FOD gathers momentum in Australian Health & Wellness Market

|

Published 26-MAR-2021 12:24 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The Food Revolution Group Limited (ASX:FOD) has provided a promising market update on the roll out of Juice Lab “Wellness Shots”, representing a massive breakthrough for FOD in establishing itself as a player within the $650M Australian Health & Wellness market.

In the past week alone, the range has been accepted by Woolworths and Metcash/ IGA.

The highlights of the roll-out to date are:

  • Juice Lab wellness shots now ranged in over 1,000 stores
  • Sales in Coles stores exceeding expectations after 4 weeks of availability
  • Woolworths has signed on the range with availability in May across both Woolworths and Woolworths Metro stores
  • Metcash list range with Foodland & Ritchies availability in April and allocation to be provided for all other IGA stores
  • Drakes in South Australia have also agreed to range in their stores and Distribution Centre

Juice Lab is the first to market with an all-natural, plant based wellness shot, positioning itself well against the dramatically increased consumer demand for preventative foods and beverages.

FOD’s roll-out of wellness products follows a US trend, where the uptake of ‘all natural, pick- me up shots and tonics’ has grown substantially on the back of the impacts of COVID-19.

Although the market is well established in the US, worth over U$4.8BN, the ‘wellness shot’ category in Australia is in its infancy.

CEO Tony Rowlinson commented, “We are delighted as to the positive response to Juice Lab Wellness shots by our retail partners. Having FOD’s largest customer Woolworths onboard is a fantastic outcome. The initial consumer offtake in Coles has been excellent and the team has done a good job meeting the increased demand.

"With consumers globally seeking products that deliver against immunity and provide functional benefits due to COVID- 19, we are well positioned with our extended range of wellness beverages and carbonated beverages to be rolled out into the market.

"Getting the Juice Lab shots ranged, provides us with the catalyst to introduce extended Juice Lab offerings.”

Juice Lab Offerings

The initial range includes:

  • Juice Lab “Focus" which contains Ginseng, guarana, calamansi & ginger
  • Juice Lab “Immunity” which contains Ginseng, turmeric & ginger
  • Juice Lab “Digest” containing apple cider, acacia & wheatgrass

Alongside Wellness Shots, Juice Lab also manufactures Juice Lab Carbonated Wellness Drinks, which are being presented to all major petrol and convenience outlets including 7- Eleven, Coles Express, Ampol, Woolworths Metro and BP.

About The Food Revolution Group

The Food Revolution Group Limited (ASX:FOD) is an Australian-based food processing company that uses a combination of conventional juice processing equipment and custom-developed equipment and processes to manufacture a range of high-quality juices, fibres, wellness beverages and supplements that are sold as branded products or ingredients to customers domestically and overseas.

FOD uses a range of processing technologies, including Current Counter Extraction (CCE) technology which was developed in conjunction with Australia’s CSIRO to extract juice from fruit and vegetables. Its processing facilities are located in Mill Park, Victoria.

FOD is aiming to generate shareholder value through exploring opportunities for growth in the functional food, beverage and nutraceutical markets in Australia and key international markets.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.

 

Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free

X